The EGF+61 polymorphism (AG and AG + GG) was associated with stable disease in both univariate and multivariate in NSCLC patients treated with first‐generation TKIs harboring EGFR‐sensitizing mutations. This evidence concerns the gene EGF and non-small cell lung carcinoma.